Spero Therapeutics Inc (SPRO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.21-0.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPRO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Extend financial runway through disciplined capital management and recent royalty financing to fund operations and capital expenditures into late 2029.
Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents were $56.1 million in 2026-Q1 and $50.8 million in 2026-Q2; the July 2026 royalty financing added $105 million in non-dilutive proceeds. Management expects these funds to support operations and capital expenditures into the second half of 2029, indicating delivery on the extended cash runway priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The company expects that its cash and cash equivalents at June 30, 2026, together with the proceeds of the royalty financing, will be sufficient to fund operating expenses and capital expenditure int…”
“Spero maintains its cash runway guidance into 2028.”
“Spero estimates that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditures into 2028.”
Develop and initiate Phase 2 clinical trial for SP001 in IgG4-related disease and explore additional immune-mediated disease opportunities.
Stated in 2 recent disclosures including 2026-Q2. The company entered an exclusive license agreement for SP001 in July 2026 and plans to initiate a Phase 2 trial in IgG4-related disease by Q2 2027. This is a new program with no reported revenue yet, so progress is in early clinical development stage, consistent with management's stated advancement plans.
“Our priorities are to advance SP001 toward a Phase 2 study in IgG4-related disease and continue evaluating additional development opportunities in immune-mediated diseases.”
Support launch and commercialization of Utebzi, the first oral carbapenem antibiotic approved for complicated urinary tract infections.
Stated in 3 consecutive quarters including 2026-Q2. The FDA approved Utebzi in June 2026, with expected US availability by end of 2026. Revenue fell from $14.2 million in 2025-Q2 to zero in 2026-Q2 due to prior deferred revenue recognition. The approval and launch preparation align with management's stated commercialization priority, showing delivery on regulatory milestones but limited current revenue contribution.
“FDA approved Utebzi, the first and only oral carbapenem antibiotic for cUTIs; expected availability by end of 2026.”
“We continue to make solid progress on the tebipenem HBr program alongside our licensing partner, GSK, as we prepare for the FDA's decision expected in June.”
“The NDA was submitted by GSK in December 2025, supported by Phase 3 PIVOT-PO trial data.”
Sustain sufficient cash and cash equivalents to fund operating expenses and capital expenditures through 2028 and into the second half of 2029.
Focus on development and commercialization of tebipenem HBr, including leveraging FDA approval and licensing agreements.
Over the trailing year it converted 0.02x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.